Treatment Information

Back

Colon Cancer treatment details. Biologic therapy.

Memorial Sloan-Kettering Cancer Center, New York, NY, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:New York, NY
Treatments:Biologic therapyHospital:Memorial Sloan-Kettering Cancer Center
Drugs:Journal:Link
Date:Jul 2010

Description:

Patients:
This phase II study involved 47 previously treated metastatic colorectal cancer patients. The median age was 62 years and 59% were male.

Treatment:
Patients were treated with the biologic therapy agent tremelimumab, which is an anti-CTLA4 monoclonal antibody that promotes attack of cancer cells by the immune system.

Toxicities:
The most severe toxicity was grade 4 thrombocytopenia. Grade 3 diarrhea, fatigue, and colitis were also reported.

Results:
The median progression-free survival was 2.3 months and median overall survival was 4.8 months.

Support:
This study was supported by Pfizer, makers of tremelimumab.

Correspondence: Dr. Ki Y. Chung; email: [email protected]



Back